These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 31321819)
1. Psychostimulant use and the brain. Lappin JM; Sara GE Addiction; 2019 Nov; 114(11):2065-2077. PubMed ID: 31321819 [TBL] [Abstract][Full Text] [Related]
2. Methamphetamine and heightened risk for early-onset stroke and Parkinson's disease: A review. Lappin JM; Darke S Exp Neurol; 2021 Sep; 343():113793. PubMed ID: 34166684 [TBL] [Abstract][Full Text] [Related]
3. Altered energy production, lowered antioxidant potential, and inflammatory processes mediate CNS damage associated with abuse of the psychostimulants MDMA and methamphetamine. Downey LA; Loftis JM Eur J Pharmacol; 2014 Mar; 727():125-9. PubMed ID: 24485894 [TBL] [Abstract][Full Text] [Related]
4. Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials. Kishi T; Matsuda Y; Iwata N; Correll CU J Clin Psychiatry; 2013 Dec; 74(12):e1169-80. PubMed ID: 24434105 [TBL] [Abstract][Full Text] [Related]
5. Enduring deficits in sustained visual attention during withdrawal of intravenous methylenedioxymethamphetamine self-administration in rats: results from a comparative study with d-amphetamine and methamphetamine. Dalley JW; Lääne K; Theobald DE; Peña Y; Bruce CC; Huszar AC; Wojcieszek M; Everitt BJ; Robbins TW Neuropsychopharmacology; 2007 May; 32(5):1195-206. PubMed ID: 17035931 [TBL] [Abstract][Full Text] [Related]
7. A comparison of psychotic symptoms in subjects with methamphetamine versus cocaine dependence. Alexander PD; Gicas KM; Willi TS; Kim CN; Boyeva V; Procyshyn RM; Smith GN; Thornton AE; Panenka WJ; Jones AA; Vila-Rodriguez F; Lang DJ; William MacEwan G; Honer WG; Barr AM Psychopharmacology (Berl); 2017 May; 234(9-10):1535-1547. PubMed ID: 28190084 [TBL] [Abstract][Full Text] [Related]
8. Behavioral and antinociceptive effects of different psychostimulant drugs in prenatally methamphetamine-exposed rats. Yamamotová A; Šlamberová R Physiol Res; 2012; 61(Suppl 2):S139-47. PubMed ID: 23130899 [TBL] [Abstract][Full Text] [Related]
9. Stimulant and Designer Drug Use: Primary Care Management. Klega AE; Keehbauch JT Am Fam Physician; 2018 Jul; 98(2):85-92. PubMed ID: 30215997 [TBL] [Abstract][Full Text] [Related]
10. Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia. Batki SL; Harris DS Am J Addict; 2004; 13(5):461-70. PubMed ID: 15764424 [TBL] [Abstract][Full Text] [Related]
11. Trace amine-associated receptor 1: A promising target for the treatment of psychostimulant addiction. Jing L; Li JX Eur J Pharmacol; 2015 Aug; 761():345-52. PubMed ID: 26092759 [TBL] [Abstract][Full Text] [Related]
12. Factors affecting severity of positive and negative symptoms of psychosis in a polysubstance using population with psychostimulant dependence. Willi TS; Honer WG; Thornton AE; Gicas K; Procyshyn RM; Vila-Rodriguez F; Panenka WJ; Aleksic A; Leonova O; Jones AA; MacEwan GW; Barr AM Psychiatry Res; 2016 Jun; 240():336-342. PubMed ID: 27138828 [TBL] [Abstract][Full Text] [Related]
13. Methamphetamine-associated psychosis: links to drug use characteristics and similarity to primary psychosis. Yang M; Yang C; Liu T; London ED Int J Psychiatry Clin Pract; 2020 Mar; 24(1):31-37. PubMed ID: 31609149 [No Abstract] [Full Text] [Related]
14. First psychotic episode risk markers for primary psychosis amongst people who use methamphetamine. McKetin R; Hides L; Kavanagh DJ; Saunders JB; Dawe S Schizophr Res; 2018 Sep; 199():456-457. PubMed ID: 29680188 [No Abstract] [Full Text] [Related]
15. [Speed users (metamphetamines): a return journey between ecstasy (MDMA) and cocaine. Clinical, preventive and health-care questions]. Royo-Isach J; Magrané M; Velilla A; Ruiz L Aten Primaria; 2004 Dec; 34(10):553-6. PubMed ID: 15607059 [No Abstract] [Full Text] [Related]
16. Cannabinoids, opioids and MDMA: neuropsychological interactions related to addiction. Robledo P Curr Drug Targets; 2010 Apr; 11(4):429-39. PubMed ID: 20017726 [TBL] [Abstract][Full Text] [Related]
17. Conditional Effects of Lifetime Alcohol Consumption on Methamphetamine-Associated Neurocognitive Performance. Saloner R; Paolillo EW; Umlauf A; Moore DJ; Heaton RK; Grant I; Cherner M; J Int Neuropsychol Soc; 2019 Sep; 25(8):787-799. PubMed ID: 31179969 [TBL] [Abstract][Full Text] [Related]
18. Characterizing prefrontal cortical activity during inhibition task in methamphetamine-associated psychosis versus schizophrenia: a multi-channel near-infrared spectroscopy study. Okada N; Takahashi K; Nishimura Y; Koike S; Ishii-Takahashi A; Sakakibara E; Satomura Y; Kinoshita A; Takizawa R; Kawasaki S; Nakakita M; Ohtani T; Okazaki Y; Kasai K Addict Biol; 2016 Mar; 21(2):489-503. PubMed ID: 25619621 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of self-reported movement dysfunction among young adults with a history of ecstasy and methamphetamine use. Todd G; Burns L; Pearson-Dennett V; Esterman A; Faulkner PL; Wilcox RA; Thewlis D; Vogel AP; White JM Drug Alcohol Depend; 2019 Dec; 205():107595. PubMed ID: 31600615 [TBL] [Abstract][Full Text] [Related]
20. Amphetamine-type Stimulants: Novel Insights into their Actions and use Patterns. Paz-Ramos MI; Cruz SL; Violante-Soria V Rev Invest Clin; 2023; 75(3):143-157. PubMed ID: 37441770 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]